Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Aug 16 2014

Volume: 384

Issue: 9943

Affiliations

[1 ] TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

[2 ] TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: msabatine@partners.org.

Article

Publisher Item ID: S0140-6736(14)61216-2

DOI: 10.1016/S0140-6736(14)61216-2

PubMed ID: 25131979

SO-VID: e01e4f77-aca8-4adf-8cd2-9e258a5ac58b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 24

See all cited by

- Version 1